维普中文期刊产品整合服务
23篇 您的检索式:作者名="WEN TF"
    题名 作者 年代 出处 被引量
1Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility:A meta-analysis显示文摘AIM: To assess the association between Interleu-kin-10 (IL-10) gene IL-10-1082 (G/A), IL-10-592(C/A), IL-10-819 (T/C) polymorphisms and hepatocellular carcinoma (HCC) susceptibility.METHODS: Two investigators independently searched the Medline, Embase, China National Knowledge Infrastructure, and Chinese Biomedicine Database. Summary odds ratios (ORs) and 95% conf idence intervals (95% CIs) for IL-10 polymorphisms and HCC were cal-culated in a fixed-effects model (the Mantel-Haenszel method) and a random-effects model (the DerSimonian and Laird method) when appropriate. RESULTS: This meta analysis included seven eligiblestudies, which included 1012 HCC cases and 2308 controls. Overall, IL-10-1082 G/A polymorphism was not associated with the risk of HCC (AA vs AG + GG, OR = 1.11, 95% CI = 0.90-1.37). When stratifying for ethnicity, the results were similar (Asian, OR = 1.12, 95% CI = 0.87-1.44; non-Asian, OR = 1.10, 95% CI = 0.75-1.60). In the overall analysis, the IL-10 polymorphism at position -592 (C/A) was identified as a genetic risk factor for HCC among Asians; patients carrying the IL-10-592*C allele had an increased risk of HCC (OR = 1.29, 95% CI = 1.12-1.49). No association was observed between the IL-10-819 T/C polymorphism and HCC susceptibility (TT vs TC + CC, OR = 1.02, 95% CI = 0.79-1.32).CONCLUSION: This meta-analysis suggests that IL-10-592 A/C polymorphism may be associated with HCC among Asians. IL-10-1082 G/A and IL-10-819 T/C polymorphisms were not detected to be related to the risk for HCC.Yong-Gang Wei, Fei Liu, Bo Li, Xi Chen, Yu Ma, Lv-Nan Yan, Tian-Fu Wen, Ming-Qing Xu, Wen-Tao Wang, Jia-Yin YangYong-Gang Wei, Fei Liu, Bo Li, Xi Chen, Yu Ma, Lv-Nan Yan, Tian-Fu Wen, Ming-Qing Xu, Wen-Tao Wang, Jia-Yin Yang, Department of Liver and Vascular Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Prov- ince, China Author contributions: Wei YG and Liu F designed the study, collected and analyzed the data and wrote the manuscript Li B collected and analyzed the data and wrote the manuscript Chen X and Ma Y collected and analyzed the data Yan LN analyzed the data and contributed to the discussion Wen TF and Xu MQ revised the manuscript Wang WT and Yang JY contributed to the discussion Wei YG and Liu F contributed equally to this work. 2011World Journal of Gastroenterology2011,17,34:3
2The effect of postoperative TA- CE on prognosis of HCC : an update 显示文摘Li KW Li X Wen TF 2013Hepatogastroenter- ology2013,60,122:1
3Outcome comparison of right hepatectomy for living liver donation versus for hepatic patients without cirrhosis显示文摘Li C Mi K Wen TF 0,,06:1
4Scoring selection criteria includingtotal tumour volume and pretransplant percentage of lymphocytesto predict recurrence of hepatocellular carcinoma after liver trans-plantation 显示文摘Li C Wen TF Yan LN 2013PLoS One2013,8,72:1
5Outcomes of patients with benign liver diseases undergoing living donor versus deceased donor liver transplantation显示文摘Li C Mi K Wen TF 0,,11:1
6A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)显示文摘Cloughesy TF Prados MD Wen PY 2008J Clin Oncol2008,,:1
7Recurrence of hepatocellular carc-inoma after liver transplantation:recurrence characteristics andrisk factors 显示文摘Li C Wen TF Liao ZX 2010Hepatogastroenterology2010,57,99100:1
8Comparison of surgical management of thoracic esophageal carcinoma between two referral centers in Japan and China显示文摘WEN TF HOICHI KATO WEN HC 2001Japanese Journal of Clinical Ontology2001,31,:1
9Phase II trial of R115777(Zarnestra) in patients with recurrent glioma not taking enzyme including antiepileptic drugs:a North American Brain Tumor Consortium report 显示文摘Cloughesy TF Kuhn J Wen p 2002Proc Annu Meet Am Soc Clin Oncol2002,21,:1
10Resection margin in hepatectomy for hepatocellular carcinoma:a systematic review显示文摘Tang YH Wen TF Chen X 0,,117:1
11Safety of synchronous hepatectomy and splenectomy for patients with hepatocellular carcinoma and hypersplenism显示文摘Wang C Li C Wen TF 2012Hepatogastroenterology2012,59,114:1
12Risk factors and outcomes of massive red blood cell transfusion following living donor liver transplantation显示文摘Li C Mi K Wen TF 2012JDig Dis2012,13,3:1
13Response criteria for glioma显示文摘Sorensen AG Batchelor TF Wen PY 20085(11):634-6442008,5,11:1
14Postoperativeneutrophil-to-lymphoeyteratioplus- pXatelet-to-lymphocyteratiopredicts the outcomes of hepatocellular carcinoma 显示文摘Li C Wen TF Yan LN 2015J Surg Res2015,198,1:1
15Phase Ⅱ trial of R115777 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing antiepileptic drugs (EIAED):a North American Brain Tumor Consortium (NABTC) report显示文摘Cloughesy TF Kuhn J Wen P 2002Proc Annu Meet Am Soc Clin Oncol2002,21,:1
16Effect of matrine on HeLa cell adhesion and migration显示文摘zhang LJ Wang TF Wen XM 2007Eur J Pharmacol2007,563,13:1
17Resection margin in hepatectomy for hepatocellular carcinoma: a systematic review显示文摘Tang YH Wen TF Chen X 2012Hepatogastroenterology2012,59,13:1
18Safety of synchronous hepatec tomy and splenectomy for patients with hepatocellular carcino- ma and hypersplenism显示文摘Wang C Li C Wen TF 2012Hepatogastroenterology2012,59,:1
19Resection margin in hepatecto- my for hepatocellular carcinoma: a systematic review 显示文摘Tang YH Wen TF Chen X 2012Hepatogastroenterology2012,59,117:1
20Dual grafts live donor livertransplantation for acute-on-chronic hepatitis B liver failure 显示文摘Chen Z Zeng Y Wen TF 2010Transplant Proc2010,42,10:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费